Similar articles

• Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.

  Dervieux T, Hancock ML, Pui CH, Rivera GK, Sandlund JT, Ribeiro RC, Boyett J, Evans WE, Relling MV. Dervieux T, et al. Clin Pharmacol Ther. 2003 Jun;73(6):506-16. doi: 10.1016/S0009-9236(03)00063-8. Clin Pharmacol Ther. 2003. PMID: 12811360 Clinical Trial.
• Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine.

  Gardiner SJ, Begg EJ, Barclay ML, Kirkpatrick CM. Gardiner SJ, et al. Adverse Drug React Toxicol Rev. 2000 Dec;19(4):293-312. Adverse Drug React Toxicol Rev. 2000. PMID: 11212460 Review. No abstract available.
• Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease.

  Bakker JA, Drent M, Bierau J. Bakker JA, et al. Curr Opin Pulm Med. 2007 Sep;13(5):458-63. doi: 10.1097/MCP.0b013e328273bc18. Curr Opin Pulm Med. 2007. PMID: 17940494 Review.
• Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.

  Gearry RB, Barclay ML. Gearry RB, et al. J Gastroenterol Hepatol. 2005 Aug;20(8):1149-57. doi: 10.1111/j.1440-1746.2005.03832.x. J Gastroenterol Hepatol. 2005. PMID: 16048561 Review.
• [Bone marrow depression after azathioprine. New discoveries on an old drug].

  Löwhagen GB, Lindstedt G. Löwhagen GB, et al. Lakartidningen. 2000 Feb 2;97(5):458-62. Lakartidningen. 2000. PMID: 10707497 Swedish.